Krystal Biotech Q3 net product rev $83.8M; VYJUVEK approvals reach 460; JNDA filed in Japan

Krystal Biotech, Inc.

2024-Q3 EPS reported $1.47 revenue$199,376,000

Net product revenue of $83.8M from VYJUVEK; $250.1M total since Aug 2023 launch.
Net income $27.2M ($0.91 diluted) vs $80.7M ($2.79) in Q3 2023; SG&A rose to $28.7M.
Cash and investments $694.2M; 460+ U.S. reimbursement approvals secured as of October.
JNDA filed for B-VEC in Japan; EMA decision expected before year end; French early access approved.
Guidance: non-GAAP R&D+SG&A $115-125M for FY2024; key pipeline data due by year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.